[Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer].
In a prospective multicenter study, four protocols for administration of mitomycin C and Adriamycin by intravesical installation were evaluated for effectiveness in the prevention of recurrent tumours in patients whose superficial bladder tumours (TA and T1) had been removed by transurethral resection. The 3-year and short-term installation protocols were compared with each other and each with a combination of the two. Evaluation after a mean follow up of 62.5 months was possible in 333 patients: the overall recurrence rate was 20.7% and the overall progression rate, 9.3%. No statistically significant differences were found in frequency of tumour recurrence among three mitomycin regimens and an Adriamycin regimen, regardless of the risk groups. However, frequency of recurrence per time unit was much lower in the treatment group with short-term intensive (weekly) mitomycin instillation, which was due mainly to prevention of late recurrence.
Schwaibold
H
H
Urologische Universitätsklinik Hamburg.
Klingenberger
H J
HJ
Huland
H
H
D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000009:adverse effects / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D016685:Mitomycin; D004317:Doxorubicin
Langzeitergebnisse einer intravesikalen Rezidivprophylaxe mit Mitomycin C und Adriamycin bei Patienten mit oberflächlichem Harnblasenkarzinom.